-+ 0.00%
-+ 0.00%
-+ 0.00%

Aktis Oncology posts presentation on AKY-2519 clinical imaging, dosimetry data for B7-H3-targeted radioconjugate

PUBT·05/27/2026 12:14:03
Listen to the news
Aktis Oncology posts presentation on AKY-2519 clinical imaging, dosimetry data for B7-H3-targeted radioconjugate
  • Aktis Oncology presented first-in-human imaging, biodistribution, and dosimetry for B7-H3 radioconjugate AKY-2519 across advanced solid tumors.
  • Early dataset showed no reported adverse events or infusion-related reactions, supporting continued clinical development.
  • Dosimetry suggested high tumor absorbed doses with low predicted exposure to critical organs, indicating a potentially wide therapeutic index for actinium-225 therapy in mCRPC.
  • Predicted salivary gland dose was low, a potential differentiation point versus PSMA-targeted radiopharmaceuticals.
  • Imaging in 34 patients showed lesion detection consistent with PSMA-11 in prostate cancer, with uptake also seen in lung cancers and colorectal cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.